Claims for Patent: 9,201,061

Summary for Patent: 9,201,061

Title:	KRT19 stabilizing HER2 and use thereof
Abstract:	Provided is a method of decreasing the stability of HER2 (human epidermal growth factor receptor 2) in a cell or individual comprising administering an effective amount of an expression or activity inhibitor of KRT19 (cytokeratin 19) to the cell or individual.
Inventor(s):	Shin; In-Cheol (Seoul, KR), Lee; Tae-Hoon (Gyeongbuk, KR), Ju; Ji-Hyun (Seoul, KR), Lee; Kyung-Min (Seoul, KR), Yang; Won-Seok (Seoul, KR)
Assignee:	INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (Seoul, KR)
Application Number:	13/777,501
Patent Claims:	1. A method of decreasing the stability of HER2 (human epidermal growth factor receptor 2) in an individual having a HER2-positive cancer comprising: administering an effective amount of an expression or activity inhibitor of KRT19 (cytokeratin 19) to the individual, wherein the activity inhibitor of KRT19 is an antibody which binds specifically to KRT19 protein. 2. The method of claim 1, wherein the expression inhibitor of KRT19 is any one selected from the group consisting of antisense oligonucleotide, short interfering RNA, short hairpin RNA, and RNAi, which binds complementarily to mRNA of KRT19 gene. 3. The method of claim 1, further comprising administering a therapeutically effective amount of an expression or activity inhibitor of HER2, wherein the activity inhibitor of HER2 is an antibody which binds specifically to HER2 protein. 4. The method of claim 3, wherein the expression inhibitor of HER2 is any one selected from the group consisting of antisense oligonucleotide, short interfering RNA, short hairpin RNA, and RNAi, which binds complementarily to mRNA of HER2 gene. 5. The method of claim 3, wherein the antibody binds specifically to HER2 protein is Herceptin. 6. A method of treating a patient having a HER2-positive cancer comprising: administering a therapeutically effective amount of an expression inhibitor of KRT19 (cytokeratin 19) or an antibody which binds specifically to KRT19 to the cancer patient. 7. The method of claim 6, wherein the HER2-positive cancer is a cancer selected from the group consisting of ovarian cancer, peritoneal cancer, fallopian tubal cancer, breast cancer, non-small cell lung cancer (NSCLC), squamous cell cancer, prostate cancer and colorectal cancer. 8. The method of claim 6, wherein the expression inhibitor of KRT19 is any one selected from the group consisting of antisense oligonucleotide, short interfering RNA, short hairpin RNA, and RNAi, which binds complementarily to mRNA of KRT19 gene. 9. The method of claim 6, further comprising administering a pharmaceutically effective amount of the expression or activity inhibitor of HER2 to the patient, wherein the activity inhibitor of HER2 in an antibody which binds specifically to HER2 protein. 10. The method of claim 9, wherein the expression inhibitor of HER2 is any one selected from the group consisting of antisense oligonucleotide, short interfering RNA, short hairpin RNA, and RNAi, which binds complementarily to mRNA of HER2 gene. 11. The method of claim 9, wherein the antibody binds specifically to HER2 protein is Herceptin.

Details for Patent 9,201,061

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-02-26